Back to SGEN Stock Lookup

SGEN Related Analyst Comments

Sep 10, 2012 12:55 PM UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)

Jul 18, 2012 01:06 PM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales

Jun 8, 2012 07:50 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review

Jun 4, 2012 08:22 AM Oppenheimer Comments on Seattle Genetics (SGEN) After 2012 ASCO

May 18, 2012 01:48 PM UBS Raises PT on Seattle Genetics (SGEN) on Adcetris Label Expansion Opportunities

May 9, 2012 12:49 PM Leerink Swann Maintains an 'Outperform' on Seattle Genetics (SGEN); Modest Growth, but Opportunities in Pipeline

Feb 14, 2012 09:33 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Uncertain 2012 Adcetris Sales Outlook

Feb 14, 2012 08:31 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Impressive First Full Quarter of Adcetris Sales

Feb 10, 2012 10:48 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Q4 Adcetris Sales Expectations

Jan 6, 2012 10:44 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2012 Preview

Jan 5, 2012 08:41 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Increasing Adcetris Estimates, But Still Disconnect Between Valuation & Potential Sales

Jan 4, 2012 11:12 AM Goldman Sachs Highlights Best and Worst in Biotech for 2012

Dec 23, 2011 07:35 AM Needham & Company 2012 Biotech Preview

Dec 15, 2011 11:41 AM Biotech M&A Will Be In Focus in 2012 - Goldman

Dec 14, 2011 07:40 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Adcetris Data in Combination with AVD Supportive of Potential Role in Front Line Therapy

Oct 25, 2011 11:47 AM Canaccord Genuity Q3 Biotech Results Preview

Oct 21, 2011 09:01 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris H2 Sales Estimate Preview

Oct 13, 2011 11:07 AM UBS maintains a 'Neutral' on Seattle Genetics (SGEN); Thoughts on Near-, Mid-, and Long-Term

Oct 12, 2011 08:57 AM Jefferies Raises Expectations on Seattle Genetics (SGEN) Adcetris Sales Following Talks with EAP Centers

Sep 19, 2011 03:39 PM RBC Doubles '11 Sales Estimate on Seattle Genetic’s (SGEN) Adcetris, Cites Recent Survey

Aug 23, 2011 09:50 AM Jefferies Ups PT on Seattle Genetics (SGEN) to $25 Following Adcetris Call; Adjusts Numbers, Outlook

Aug 23, 2011 08:30 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris Launch Ahead

Aug 22, 2011 03:06 PM Needham & Company Reiterates a 'Buy' on Seattle Genetics; As the School Year Begins, So Does Commercial Life for SGEN

Aug 22, 2011 08:43 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Adcetris Label Supports Limited Market Opportunity

Aug 22, 2011 08:14 AM Jefferies Comments on FDA Approval of Seattle Genetics (SGEN) Adcetris, Better-Than-Expected

Jul 19, 2011 08:31 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Profile Shift Expected to Weigh on Shares

Jul 15, 2011 10:03 AM Jefferies Boosts PT on Seattle Genetics (SGEN) Following FDA Panel Vote; Is Buyer on Weakness

Jul 12, 2011 03:33 PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS

Jul 11, 2011 08:38 AM Canaccord Genuity Reiterates a 'Sell' on Seattle Genetics (SGEN); Adcetris ODAC Panel Preview

Jun 16, 2011 08:25 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); Current Valuation Overrepresents Ultimate Market Opportunity

Jun 8, 2011 08:07 AM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); ASCO Meeting Highlights Include Durable Responses Induced By B. Vedotin

Jun 6, 2011 07:25 AM Jefferies Reiterates Bullish Stance On Seattle Genetics (SGEN) Related To Eventual Adcentris Label

May 19, 2011 08:24 AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO

May 6, 2011 01:55 PM UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); What We Learned from the 1Q11 Call

May 6, 2011 09:45 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising PT

Apr 12, 2011 07:39 AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference

Feb 18, 2011 10:01 AM Canaccord Genuity Reiterates a 'Sell' on Seattle Genetics (SGEN); ADC Technology Drug Candidate Falls Flat

Feb 9, 2011 11:48 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); SGN-35 Market Potential Concerns Persist

Feb 9, 2011 10:39 AM UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); Updating Model for 4Q10 Results

Feb 9, 2011 08:45 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Trials/Other Pipeline Data Set the 2011 Mission

Jan 5, 2011 08:26 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2011 May Be a Transformational Year

Dec 6, 2010 07:59 AM Needham & Company reiterates a 'Buy' on Seattle Genetics (SGEN); B is for BLA, and Ved is for Very Exemplary Data - Pivotal Trial Results

Nov 22, 2010 11:05 AM Canaccord Genuity Maintains a 'Sell' on Seattle Genetics (SGEN); ASH Preview: High Expectations Going Into Data Presentations

Nov 2, 2010 03:28 PM Canaccord Genuity Downgrades Seattle Genetics (SGEN) from Buy to Sell; SGN-35 Revaluated

Nov 2, 2010 08:17 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN)

Sep 28, 2010 01:04 PM UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); Strong Results in Hodgkin Lymphoma

Sep 27, 2010 11:13 AM Needham & Company Lifts Target On Seattle Genetics (SGEN) Following Positive Data

Sep 14, 2010 10:25 AM UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); Lintuzumab Development Discontinued

Sep 13, 2010 08:50 AM Needham & Company Defending Seattle Genetics (SGEN); Remain Positively Inclined Towards B. vedotin and Current ADC Platform

Jul 28, 2010 08:07 AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Anticipation of Sentinel Clinical Trial Events Expected in 2H10

Back to SGEN Stock Lookup